AbbVie: Dominating Immunology While Building Oncology Upside
Source: SeekingAlpha
2026-02-17 01:11:27 ET
AbbVie ( ABBV ), a leader in the JAK and IL-23 inhibitor markets, released strong Q4 numbers, but its stock price fell 5.1% that day. And first, I will note the dry numbers....
Read the full article on Seeking Alpha
For further details see:
AbbVie: Dominating Immunology While Building Oncology Upside
Sanofi
NASDAQ: SNY
SNY Trading
-0.56% G/L:
$44.155 Last:
1,077,036 Volume:
$44.07 Open:
SNY Latest News
February 23, 2026 01:42:29 pm
Kraig Biocraft Laboratories Featured on the Cover of National Geographic
February 18, 2026 08:45:56 am
It's Not Synthetic, It's Real. Kraig Labs Nears Spider Silk Breakthrough
SNY Stock Data
$119,804,457,217
2,430,957,423
N/A
389
N/A
Pharmaceuticals
Healthcare
FR
Paris
